Oxford Biomedica (LON:OXB – Get Free Report) had its price target decreased by investment analysts at Royal Bank Of Canada from GBX 1,170 to GBX 1,140 in a research note issued to investors on Wednesday,Digital Look reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target suggests a potential upside of 85.37% from the stock’s previous close.
A number of other equities research analysts have also recently weighed in on the stock. Stifel Nicolaus restated a “buy” rating and issued a GBX 950 price objective on shares of Oxford Biomedica in a report on Wednesday, March 11th. Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 target price on shares of Oxford Biomedica in a report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 600.04.
Get Our Latest Analysis on Oxford Biomedica
Oxford Biomedica Stock Up 2.5%
Oxford Biomedica (LON:OXB – Get Free Report) last issued its quarterly earnings results on Thursday, March 26th. The biopharmaceutical company reported GBX (26.92) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 48.56% and a negative net margin of 17.85%. On average, equities analysts predict that Oxford Biomedica will post -31.0799998 EPS for the current fiscal year.
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.
See Also
- Five stocks we like better than Oxford Biomedica
- Chevron’s Microsoft Deal Turns Natural Gas Into an AI Trade
- Why nVent Could Be a Long-Term AI Infrastructure Winner
- Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning
- Apple’s Intel Deal Arrives at the Right Time for Its Stock
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.
